Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Cutaneous T-cell Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy